| The binding of PKCepsilon and MEG2 to STAT3 regulates IL-6-mediated microglial hyperalgesia during inflammatory pain. | The binding of PKCε and MEG2 to STAT3 regulates IL-6-mediated microglial hyperalgesia during inflammatory pain.
Li X, Wang J, Liao C, Yang X, Zhao Z, Liu Y, Xue Q, Luo Y, Liu X, Liu Z. | 04/26/2024 |
| Signature of miR-21 and MEG-2 and their correlation with TGF-beta signaling in breast cancer. | Signature of miR-21 and MEG-2 and their correlation with TGF-β signaling in breast cancer.
Desouky EM, Khaliefa AK, Hozayen WG, Shaaban SM, Hasona NA. | 02/27/2023 |
| CircMMD_007 promotes oncogenic effects in the progression of lung adenocarcinoma through microRNA-197-3p/protein tyrosine phosphatase non-receptor type 9 axis. | CircMMD_007 promotes oncogenic effects in the progression of lung adenocarcinoma through microRNA-197-3p/protein tyrosine phosphatase non-receptor type 9 axis.
Zhu L, Guo T, Chen W, Lin Z, Ye M, Pan X., Free PMC Article | 04/16/2022 |
| PTPN9-mediated dephosphorylation of VTI1B promotes ATG16L1 precursor fusion and autophagosome formation. | PTPN9-mediated dephosphorylation of VTI1B promotes ATG16L1 precursor fusion and autophagosome formation.
Chou HY, Lee YT, Lin YJ, Wen JK, Peng WH, Hsieh PL, Lin SY, Hung CC, Chen GC., Free PMC Article | 04/16/2022 |
| Effect of L3MBTL3/PTPN9 polymorphisms on risk to alcohol-induced ONFH in Chinese Han population. | Effect of L3MBTL3/PTPN9 polymorphisms on risk to alcohol-induced ONFH in Chinese Han population.
Xiong J, Niu Y, Liu W, Zeng F, Cheng JF, Chen SQ, Zeng XZ. | 03/26/2022 |
| The Critical Role of the miR-21-MEG2 Axis in Colorectal Cancer. | The Critical Role of the miR-21-MEG2 Axis in Colorectal Cancer.
Bao Z, Gao S, Zhang B, Shi W, Li A, Tian Q. | 08/28/2021 |
| Low MEG2 expression is associated with metastasis of hepatocellular carcinoma. | MEG2 inhibits the growth and metastasis of hepatocellular carcinoma by inhibiting AKT pathway.
Ying D, Ruan Y, Zhou X. | 01/19/2019 |
| Results from a study on gene expression variability markers in early-stage human embryos shows that PTPN9 is a putative expression variability marker for the 3-day, 8-cell embryo stage. | Variability of Gene Expression Identifies Transcriptional Regulators of Early Human Embryonic Development.
Hasegawa Y, Taylor D, Ovchinnikov DA, Wolvetang EJ, de Torrenté L, Mar JC., Free PMC Article | 07/23/2018 |
| this study highlights an important role for miR-96 in the regulation of PTPN9 in breast cancer cells and may provide insight into the molecular mechanisms of breast carcinogenesis. | miR-96 promotes cell proliferation, migration and invasion by targeting PTPN9 in breast cancer.
Hong Y, Liang H, Uzair-Ur-Rehman, Wang Y, Zhang W, Zhou Y, Chen S, Yu M, Cui S, Liu M, Wang N, Ye C, Zhao C, Liu Y, Fan Q, Zhang CY, Sang J, Zen K, Chen X., Free PMC Article | 05/19/2018 |
| Expression of MEG2 is reversely correlated with that of miR-181a-5p in gastric cancer. | MEG2 is regulated by miR-181a-5p and functions as a tumour suppressor gene to suppress the proliferation and migration of gastric cancer cells.
Liu Z, Sun F, Hong Y, Liu Y, Fen M, Yin K, Ge X, Wang F, Chen X, Guan W., Free PMC Article | 04/21/2018 |
| PTPN9 inhibited cell proliferation in HepG2 cells. | Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression.
Hu B, Yan X, Liu F, Zhu C, Zhou H, Chen Y, Liu J, Gu X, Ni R, Zhang T. | 03/18/2017 |
| PTPMeg2 is an important phosphatase for the dephosphorylation of STAT3 and plays a critical role in breast cancer development. | Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer.
Su F, Ren F, Rong Y, Wang Y, Geng Y, Wang Y, Feng M, Ju Y, Li Y, Zhao ZJ, Meng K, Chang Z., Free PMC Article | 04/27/2013 |
| This study indentified VEGFR2 as a PTPN9 substrate, and indicated that PTPN9 is a negative regulator of VEGFR2 signaling and function in endothelial cells. | Tyrosine phosphatase PTP-MEG2 negatively regulates vascular endothelial growth factor receptor signaling and function in endothelial cells.
Hao Q, Samten B, Ji HL, Zhao ZJ, Tang H., Free PMC Article | 12/8/2012 |
| data suggest PTPN9 as a negative regulator of breast cancer cells by targeting ErbB2 and EGFR and inhibiting STAT activation | Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells.
Yuan T, Wang Y, Zhao ZJ, Gu H., Free PMC Article | 06/28/2010 |
| PTP-MEG2 has an important role in the development of erythroid cells. | PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells.
Xu MJ, Sui X, Zhao R, Dai C, Krantz SB, Zhao ZJ. | 01/21/2010 |
| the N terminus of PTPMEG2 is necessary for the targeting of this phosphatase to the secretory vesicle compartment by association with other proteins involved in intracellular transport. | Association of protein-tyrosine phosphatase MEG2 via its Sec14p homology domain with vesicle-trafficking proteins.
Saito K, Williams S, Bulankina A, Höning S, Mustelin T. | 01/21/2010 |
| PTPase-MEG2 through its Sec14p homology domain couples inositide phosphorylation to tyrosine dephosphorylation and the regulation of intracellular traffic of the secretory pathway in T cells. | Homotypic secretory vesicle fusion induced by the protein tyrosine phosphatase MEG2 depends on polyphosphoinositides in T cells.
Huynh H, Wang X, Li W, Bottini N, Williams S, Nika K, Ishihara H, Godzik A, Mustelin T. | 01/21/2010 |
| Purification and characterization of protein tyrosine phosphatase PTP-MEG2 | Purification and characterization of protein tyrosine phosphatase PTP-MEG2.
Qi Y, Zhao R, Cao H, Sui X, Krantz SB, Zhao ZJ. | 01/21/2010 |
| PTP-MEG2 reduced the phosphotyrosine content of NSF and co-localized with NSF and syntaxin 6 in intact cells, the first demonstrated role for a protein tyrosine phosphatase in the regulated secretory pathway | Control of vesicle fusion by a tyrosine phosphatase.
Huynh H, Bottini N, Williams S, Cherepanov V, Musumeci L, Saito K, Bruckner S, Vachon E, Wang X, Kruger J, Chow CW, Pellecchia M, Monosov E, Greer PA, Trimble W, Downey GP, Mustelin T. | 01/21/2010 |
| role in the negative regulation of hepatic insulin signaling | Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling.
Cho CY, Koo SH, Wang Y, Callaway S, Hedrick S, Mak PA, Orth AP, Peters EC, Saez E, Montminy M, Schultz PG, Chanda SK. | 01/21/2010 |